Evaluation of miRNA 130a-3P and miRNA 301a-3P in Egyptian patients with urinary bladder carcinoma

Abstract

Objectives

To study the role of microRNA 130a-3p and microRNA 301a-3p in urinary bladder carcinoma.

Background

Despite the discovery of several clinical and molecular indicators for predicting outcomes in bladder cancer, it is unclear how to use these indicators in clinical practice. A recent study revealed that the miR-130 family may play a vital role in the occurrence and development of BC by regulating signal pathways through various target genes. We intend to apply them as novel, nonintrusive, and easily detectable bladder cancer indicators.

Subjects and methods

The current study involved one hundred subjects. Fifty subjects had bladder cancer diagnosed by cystoscope biopsy and histopathological examination, and the other fifty were age- and gender-matched healthy adults serving as a control group. All participants were subjected to complete history taking through medical examination and estimation of expression levels of plasma miRNA 130a-3p by reverse transcriptase – polymerase chain reaction (RT-PCR) through quantitative real-time technique.

Results

miRNA 130a-3p and miRNA 301a-3p were expressed at higher levels in the plasma of bladder cancer patients than in the controls. The points for the diagnostic capacities of miR 130a-3p and miR 301a-3p for bladder cancer were > 0.921 and > 1.32, respectively, indicating that they are potential clinical diagnostic biomarkers for bladder cancer with good sensitivity and specificity. Moreover, stage IIIA versus stage IIIB can be discriminated as >0.96 (miR 130a-3p) and > 2.48 (miR 301a-3p), which can be utilized for estimating the clinical prognosis of bladder cancer.

Conclusion

miRNA 130a-3p and miRNA 301a-3p expression levels in plasma can differentiate bladder cancer patients from healthy controls and discriminate between stage IIIA and stage IIIB. This finding may facilitate the clinical diagnosis of bladder cancer.